CA
MRTX

Corrado Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Corrado Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$37K – 124
2017
Q2 		$37K Buy
+10,000
New +$38.3K 0.02% 115

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Corrado Advisors's MRTX Position: Q3 2017 in Review

Corrado Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2017, closing a stake of 10,000 shares — an estimated $37K sold.

Corrado Advisors first reported a position in MRTX in Q2 2017 and held it in 1 quarter. The position peaked at $37K in Q2 2017. 49 funds tracked by Wall St. Rank hold MRTX as of Q3 2017.

  • Corrado Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Corrado Advisors sold 10,000 Mirati Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $37K.
  • Corrado Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Corrado Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $37K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Corrado Advisors's 13F filing for Q3 2017, filed 6 Oct 2017.